|
1
|
Coughlin SS: Epidemiology of breast cancer
in women. Adv Exp Med Biol. 1152:9–29. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cheung KL: Treatment strategies and
survival outcomes in breast cancer. Cancers (Basel). 12:7352020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Falzone L, Grimaldi M, Celentano E,
Augustin LSA and Libra M: Identification of modulated MicroRNAs
associated with breast cancer, diet, and physical activity. Cancers
(Basel). 12:25552020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Arnedos M, Roulleaux Dugage M,
Perez-Garcia J and Cortes J: Window of opportunity trials for
biomarker discovery in breast cancer. Curr Opin Oncol. 31:486–492.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Emens LA: Breast cancer immunotherapy:
Facts and hopes. Clin Cancer Res. 24:511–520. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhong A, Tan FQ and Yang WX:
Chromokinesin: Kinesin superfamily regulating cell division through
chromosome and spindle. Gene. 589:43–48. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hirokawa N and Tanaka Y: Kinesin
superfamily proteins (KIFs): Various functions and their relevance
for important phenomena in life and diseases. Exp Cell Res.
334:16–25. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lucanus AJ and Yip GW: Kinesin
superfamily: Roles in breast cancer, patient prognosis and
therapeutics. Oncogene. 37:833–838. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fu Y, Zhou QZ, Zhang XL, Wang ZZ and Wang
P: Identification of Hub genes using co-expression network analysis
in breast cancer as a tool to predict different stages. Med Sci
Monit. 25:8873–8890. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li TF, Zeng HJ, Shan Z, Ye RY, Cheang TY,
Zhang YJ, Lu SH, Zhang Q, Shao N and Lin Y: Overexpression of
kinesin superfamily members as prognostic biomarkers of breast
cancer. Cancer Cell Int. 20:1232020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jiang J, Liu T, He X, Ma W, Wang J, Zhou
Q, Li M and Yu S: Silencing of KIF18B restricts proliferation and
invasion and enhances the chemosensitivity of breast cancer via
modulating Akt/GSK-3β/β-catenin pathway. Biofactors. 47:754–767.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miniowitz-Shemtov S, Eytan E, Kaisari S,
Sitry-Shevah D and Hershko A: Mode of interaction of TRIP13
AAA-ATPase with the Mad2-binding protein p31comet and with mitotic
checkpoint complexes. Proc Natl Acad Sci USA. 112:11536–11540.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu S, Qian J, Guo M, Gu C and Yang Y:
Insights into a Crucial Role of TRIP13 in human cancer. Comput
Struct Biotechnol J. 17:854–861. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dazhi W, Mengxi Z, Fufeng C and Meixing Y:
Elevated expression of thyroid hormone receptor-interacting protein
13 drives tumorigenesis and affects clinical outcome. Biomark Med.
11:19–31. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang K, Sturt-Gillespie B, Hittle JC,
Macdonald D, Chan GK, Yen TJ and Liu ST: Thyroid hormone receptor
interacting protein 13 (TRIP13) AAA-ATPase is a novel mitotic
checkpoint-silencing protein. J Biol Chem. 289:23928–23937. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vedoya GM, López Nigro MM and Martín GA:
The secretome of non-tumorigenic mammary cells MCF-10A elicits DNA
damage in MCF-7 and MDA-MB-231 breast cancer cells. Toxicol In
Vitro. 70:1050182021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
van den Brand AD, Villevoye J, Nijmeijer
SM, van den Berg M and van Duursen MBM: Anti-tumor properties of
methoxylated analogues of resveratrol in malignant MCF-7 but not in
non-tumorigenic MCF-10A mammary epithelial cell lines. Toxicology.
422:35–43. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gobin E, Bagwell K, Wagner J, Mysona D,
Sandirasegarane S, Smith N, Bai S, Sharma A, Schleifer R and She
JX: A pan-cancer perspective of matrix metalloproteases (MMP) gene
expression profile and their diagnostic/prognostic potential. BMC
Cancer. 19:5812019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Barzaman K, Karami J, Zarei Z,
Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E and
Farahmand L: Breast cancer: Biology, biomarkers, and treatments.
Int Immunopharmacol. 84:1065352020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tsang JYS and Tse GM: Molecular
classification of breast cancer. Adv Anat Pathol. 27:27–35. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lyons TG: Targeted therapies for
triple-negative breast cancer. Curr Treat Options Oncol. 20:822019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang B, Wang S, Xie H, Wang C, Gao X, Rong
Y, Liu Z and Lu Y: KIF18B promotes hepatocellular carcinoma
progression through activating Wnt/β-catenin-signaling pathway. J
Cell Physiol. 235:6507–6514. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu Y, Wang A, Zhu B, Huang J, Lu E, Xu H,
Xia W, Dong G, Jiang F and Xu L: KIF18B promotes tumor progression
through activating the Wnt/β-catenin pathway in cervical cancer.
Onco Targets Ther. 11:1707–1720. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Krishnamurthy N and Kurzrock R: Targeting
the Wnt/beta-catenin pathway in cancer: Update on effectors and
inhibitors. Cancer Treat Rev. 62:50–60. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tian D, Tian M, Ma ZM, Zhang LL, Cui YF
and Li JL: Anesthetic propofol epigenetically regulates breast
cancer trastuzumab resistance through IL-6/miR-149-5p axis. Sci
Rep. 10:88582020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li ZH, Lei L, Fei LR, Huang WJ, Zheng YW,
Yang MQ, Wang Z, Liu CC and Xu HT: TRIP13 promotes the
proliferation and invasion of lung cancer cells via the Wnt
signaling pathway and epithelial-mesenchymal transition. J Mol
Histol. 52:11–20. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Agarwal S, Behring M, Kim HG,
Chandrashekar DS, Chakravarthi BVSK, Gupta N, Bajpai P, Elkholy A,
Al Diffalha S, Datta PK, et al: TRIP13 promotes metastasis of
colorectal cancer regardless of p53 and microsatellite instability
status. Mol Oncol. 14:3007–3029. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu X, Shen X and Zhang J: TRIP13 exerts a
cancer-promoting role in cervical cancer by enhancing Wnt/β-catenin
signaling via ACTN4. Environ Toxicol. 36:1829–1840. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu J, Zhou L, Wei B, Qian Z, Wang J, Hui
H and Sun Y: MiR-142-5p inhibits pancreatic cancer cell migration
and invasion by targeting PIK3CA. Mol Med Rep. 22:2085–2092. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang S, Sun S, Xu W, Yu B, Wang G and Wang
H: Astragalus polysaccharide inhibits breast cancer cell migration
and invasion by regulating epithelial-mesenchymal transition via
the Wnt/β-catenin signaling pathway. Mol Med Rep. 21:1819–1832.
2020.PubMed/NCBI
|
